RNS3 Feb 2020 07:15
"Dr Keith Flaherty, Professor of Medicine at Harvard Medical School and Director of Clinical Research at Massachusetts General Hospital Cancer Center, and clinical advisor to Scancell commented: “Although checkpoint inhibitor combinations have improved outcomes for patients with melanoma, the toxicity of combinations such as ipilimumab plus nivolumab means that there remains a need to develop combinations with other investigational agents such as SCIB1, which have the potential to improve response rates without increasing toxicity.”
Dr Cliff Holloway, Chief Executive Officer, Scancell, commented: “We are delighted that our IND is now open, allowing us to progress our SCIB1 Phase 2 trial in the US as well as the UK. Approval will allow us to increase our overall patient recruitment rate and determine whether the addition of SCIB1 to current, standard of care treatment with pembrolizumab increases the anti-cancer response rate in patients with metastatic melanoma.”
Good news indeed - let's hope they can find some Patients to dose . . .